Trial Profile
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Zolbetuximab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms GLOW
- Sponsors Astellas Pharma Global Development
- 26 Mar 2024 According to an Astellas Pharma media release, company has also submitted applications for VYLOY to regulatory agencies around the world, and review is ongoing.
- 26 Mar 2024 According to an Astellas Pharma media release, the study enrolled 507 patients at 166 study locations in the U.S., Canada, United Kingdom, Europe, South America, and Asia, including Japan.
- 26 Mar 2024 According to an Astellas Pharma media release, company announced that the Japans Ministry of Health, Labour and Welfare (MHLW) approved VYLOY (zolbetuximab) for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. VYLOY is the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world. The approval is based on results from the Phase 3 SPOTLIGHT and GLOW clinical trials.